Utrecht, The Netherlands-based ViCentra initially closed its Series D in September, bringing in $85 million. The now-closed extension to the financing brings the total raised to $98 million. CEO Tom Arnold explained the company’s plans for a big commercial push with the funds in an interview with Drug Delivery Business News after the initial closing.
ViCentra said the additional funding follows “a strong year of commercial and operational progress.” It includes new capital from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech. Existing investor Innovation Industries also took part in the second closing.
Get the full story at our sister site, Drug Delivery Business News.
